文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

复发性肾细胞癌的综合全程管理策略：病例报告与文献综述

Comprehensive Whole-Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review.

作者信息

Hu PengNan, Chen Di, Yu Jun, Mi Hua

机构信息

Department of Urology The First Affiliated Hospital of Guangxi Medical University Nanning China.

出版信息

Clin Case Rep. 2025 May 1;13(5):e70418. doi: 10.1002/ccr3.70418. eCollection 2025 May.

DOI:10.1002/ccr3.70418
PMID:40321230
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12045782/
Abstract

Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade-long expertise in managing recurrent cases, we advocate the adoption of Programmed Death-1 (PD-1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious treatment option.

摘要

肾细胞癌是一种具有高复发率和转移性的恶性肿瘤。凭借在处理复发病例方面长达十年的专业经验，我们主张在阿昔替尼单药治疗无法抑制肿瘤转移时，采用程序性死亡受体 1（PD-1）抑制剂联合阿昔替尼，从而为医生提供一种有效的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/8e90a1a15a48/CCR3-13-e70418-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/617a18ee0443/CCR3-13-e70418-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/4210e42b2acb/CCR3-13-e70418-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/b42cbe59394a/CCR3-13-e70418-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/4a80e2dbc7c1/CCR3-13-e70418-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/b6489220ebf8/CCR3-13-e70418-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/56fe365711ab/CCR3-13-e70418-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/48b41d5866d9/CCR3-13-e70418-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/8e90a1a15a48/CCR3-13-e70418-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/617a18ee0443/CCR3-13-e70418-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/4210e42b2acb/CCR3-13-e70418-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/b42cbe59394a/CCR3-13-e70418-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/4a80e2dbc7c1/CCR3-13-e70418-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/b6489220ebf8/CCR3-13-e70418-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/56fe365711ab/CCR3-13-e70418-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/48b41d5866d9/CCR3-13-e70418-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e8/12045782/8e90a1a15a48/CCR3-13-e70418-g008.jpg

相似文献

[1]
Comprehensive Whole-Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review.

Clin Case Rep. 2025-5-1

[2]
Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.

Oncol Lett. 2019-4

[3]
Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

PLoS One. 2023

[4]
Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.

In Vivo. 2020

[5]
Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma.

Front Immunol. 2021

[6]
Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience.

Medicine (Baltimore). 2023-10-13

[7]
[Risk-adapted therapy for metastatic renal cell carcinoma].

Urologe A. 2020-2

[8]
Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.

J Med Case Rep. 2022-5-18

[9]
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Cancer Med. 2021-4

[10]
Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.

Int J Clin Oncol. 2020-6-2

本文引用的文献

[1]
Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2024-5-11

[2]
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data.

Support Care Cancer. 2023-10-11

[3]
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.

Eur Urol Oncol. 2023-6

[4]
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy.

Int Immunopharmacol. 2022-12

[5]
Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.

Curr Probl Cancer. 2022-8

[6]
Cancer statistics in China and United States, 2022: profiles, trends, and determinants.

Chin Med J (Engl). 2022-2-9

[7]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[8]
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.

Future Oncol. 2021-7

[9]
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Cancer. 2020-9-15

[10]
Trigeminal Ganglion Metastasis of Renal Clear Cell Carcinoma: Cases Report and Review of the Literature.

World Neurosurg. 2019-5-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索